Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Krystal Biotech Stock Up 1.2%
Shares of NASDAQ:KRYS opened at $332.27 on Friday. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54. The company has a 50-day moving average price of $344.39 and a 200 day moving average price of $299.25. The company has a market cap of $9.83 billion, a P/E ratio of 41.64 and a beta of 0.53.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Analysts expect that Krystal Biotech, Inc. will post 7.68 EPS for the current year.
Institutional Trading of Krystal Biotech
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on KRYS. Royal Bank Of Canada began coverage on Krystal Biotech in a report on Friday. They set an “outperform” rating and a $400.00 price objective on the stock. Evercore reissued an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. HC Wainwright boosted their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Bank of America increased their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, TD Cowen raised their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $365.40.
Read Our Latest Stock Report on Krystal Biotech
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
